You are here: Home: PCU 1 | 2006: PCU 1 | 2006 Audio
 
  Go to interview with Mark S Soloway, MD
Go to interview with Gregory S Merrick, MD
Go to interview with Richard G Stock, MD
Go to interview with Anna C Ferrari, MD
  To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Mark S Soloway, MD
Professor and Chair
Department of Urology
Miller School of Medicine
University of Miami
Miami, Florida		  
  Click here to download the entire segment  
Track 1 Introduction
Track 2 Surgery versus radiation therapy for patients with intermediate-risk prostate cancer
Track 3 Use of androgen deprivation therapy for patients with intermediate-risk prostate cancer
Track 4 Impact of age and body type on selection of patients for radical prostatectomy
Track 5 Use of adjuvant androgen deprivation for patients with higher-risk disease
Track 6 Postprostatectomy treatment options for patients with positive margins

Track 7 PSA recurrence rates after radical prostatectomy with positive margins
Track 8 Treatment options for patients with seminal vesicle invasion
Track 9 Radiation therapy following PSA recurrence after radical prostatectomy
Track 10 Earlier versus later use of androgen deprivation therapy for patients with PSA-only recurrence
Track 11 Maximal androgen blockade as a therapeutic option
Track 12 Treatment options following PSA rise after primary external beam therapy
Track 13 Urologists’ and radiation oncologists’ perception of the benefits and tolerability of chemotherapy for prostate cancer
Track 14 Incorporation of docetaxel earlier in the treatment of prostate cancer
     
Gregory S Merrick, MD
Medical Director
Schiffler Cancer Center
Wheeling Jesuit University
Wheeling, West Virginia		  
  Click here to download the entire segment  
Track 1 Introduction
Track 2 Influence of PSA velocity on survival after local therapy
Track 3 Therapeutic approach to patients with low-risk disease
Track 4 Brachytherapy techniques
Track 5 Medical management of patients treated with brachytherapy
Track 6 Erectile dysfunction in patients treated with brachytherapy

Track 7 PSA levels after brachytherapy
Track 8 Clinical algorithm for the treatment of patients with high-risk disease
Track 9 Clinical and research strategies for patients with intermediate-risk disease
Track 10 Postprostatectomy radiation therapy
Track 11 Management of PSA recurrence
Track 12 Future role of chemotherapy for patients with prostate cancer
Track 13 Key current research questions in prostate cancer
Track 14 Brachytherapy with or without external beam radiation therapy in patients with intermediate-risk disease
Track 15 Case discussion: A 58-year-old man with Gleason 8 prostate cancer and seminal vesicle invasion
Track 16 Rehabilitation after brachytherapy
     
Richard G Stock, MD
Professor and Chair
Department of Radiation Oncology
Mount Sinai School of Medicine
New York, New York		  
  Click here to download the entire segment  
Track 1 Introduction
Track 2 Long-term follow-up of brachytherapy
Track 3 Long-term outcomes of brachytherapy, external beam irradiation and hormonal therapy for patients with higher-risk disease
Track 4 Genetic susceptibility to radiation therapy toxicity
Track 5 Treatment of high-risk disease with long-term hormonal therapy
Track 6 Clinical use of postprostatectomy radiation therapy

Track 7 Evaluation of PSA after radiation therapy
Track 8 Reduction of urinary side effects with the real-time intraoperative brachytherapy technique
Track 9 Number of brachytherapy implants performed to acquire proficiency
Track 10 Therapeutic approach to patients with PSA progression
Track 11 Future directions in the delivery of radiation therapy
Track 12 Selection of patients for watchful waiting
Track 13 Impact of therapies to optimize local control and patterns of disease failure
     
Anna C Ferrari, MD
Associate Professor
Director of Genitourinary Cancer Program
Division of Hematology/Oncology
Derald H Ruttenberg Cancer Center
Mount Sinai School of Medicine
New York, New York		  
  Click here to download the entire segment  
Track 1 Introduction
Track 2 Clinical trials of docetaxel-based chemotherapy for advanced prostate cancer
Track 3 Clinical experience with docetaxel in prostate cancer
Track 4 Tolerability of docetaxel chemotherapy
Track 5 Use of chemotherapy for patients with PSA progression
Track 6 Patterns of medical oncology referral in prostate cancer treatment
Track 7 Efficacy of chemotherapy in the treatment of prostate cancer relative to other common solid tumors
Track 8 Future directions in prostate cancer clinical research
Track 9 Duration of endocrine therapy for patients with high-risk disease
Track 10 Clinical use of maximal androgen blockade
Track 11 Bicalutamide monotherapy